Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Summary

To evaluate the safety and efficacy of PF-04217329.

Timeline

Start

2007-12-11

Primary completion

2009-06-26

Completion

2009-06-26

Outcome

Mixed primary results

paper Stage I at day 14: statistically significantly greater IOP reductions were observed at all taprenepag isopropyl doses versus vehicle. PMID 21851167 ↗

registry Latanoprost Vehicle and Taprenepag 0.005% (Stage II) vs Latanoprost 0.005% and Taprenepag Vehicle (Stage II); p = 0.171 NCT00572455 ↗

registry Latanoprost 0.005% and Taprenepag 0.01% (Stage II) vs Latanoprost 0.005% and Taprenepag Vehicle (Stage II); p <0.001 NCT00572455 ↗

Publications

• Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17. doi: 10.3109/02713683.2011.593725.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latanoprost	Small molecule	0.005 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.0025 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.005 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.01 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.015 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.02 %	Topical
Subject	taprenepag isopropyl	Small molecule	0.03 %	Topical

Indications